Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review

摘要

Abstract Small molecule inhibitors of adipocyte fatty acid binding protein 4 (FABP4) have attracted interest following the recent publications of beneficial pharmacological effects of these compounds. FABP4 is predominantly expressed in macrophages and adipose tissue where it regulates fatty acids (FAs) storage and lipolysis and is an important mediator of inflammation. In the past years, hundreds FABP4 inhibitors have been synthesized for effective atherosclerosis and diabetes treatments, including derivatives of niacin, quinoxaline, aryl-quinoline, bicyclic pyridine, urea, aromatic compounds and other novel heterocyclic compounds. This review provides an overview of the synthesized and discovered molecules as adipocyte fatty acid binding protein 4 inhibitors (FABP4is) since the synthesis of the putative FABP4i, BMS309403, highlighting the interactions of the different classes of inhibitors with the targets. Graphical abstract Display Omitted Highlights ? The discovery of adipocyte fatty acid binding protein inhibitors has been reviewed. ? We presented an updated literature from 2004 to May 2017. ? Described interactions of the different classes of inhibitors with FABP4.